Comparison of the ELISA method with the nephelometric method for determination of serum amyloid A in patients with COVID 19

Scand J Clin Lab Invest. 2023 Feb;83(1):60-63. doi: 10.1080/00365513.2022.2150983. Epub 2022 Nov 30.

Abstract

This study aimed to examine the agreement of the serum amyloid A (SAA) values determined using the ELISA test and the nephelometric automated method. This study included 80 serum samples obtained from patients with COVID-19. Samples were determined using ELISA and the nephelometric method. Wilcoxon signed ranks test showed a statistically significant difference in the calculated median values (Z = -2.432, p = 0.015). The correlation between methods was statistically significant (r = 0.603, p < 0.0001). Bland Altman analysis showed a bias of 56.6 mg/L and a relative bias of 7.4% between the methods. The results of this study indicate that further studies are needed that will examine the compliance between the ELISA and the nephelometric method for determining SAA, and the results must be carefully interpreted based on the method used.

Keywords: COVID-19; ELISA; Serum amyloid A; methods comparison; nephelometry.

MeSH terms

  • COVID-19* / diagnosis
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Nephelometry and Turbidimetry
  • Serum Amyloid A Protein* / analysis

Substances

  • Serum Amyloid A Protein